Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PTN - Palatin Technologies Inc. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (31)	4/20/2001 12:29:26 PM
From: tuck	Respond to of 142

Another entrant in the ED race: >>Friday April 20, 8:02 am Eastern Time Press Release SOURCE: Senetek PLC Study Shows Senetek PLC's Invicorp Well-Tolerated as Treatment for Erectile Dysfunction in Men With High Blood Pressure NAPA, Calif., April 20 /PRNewswire Interactive News Release/ -- Senetek PLC (Nasdaq: SNTKY - news), senetekplc.com , which develops products in two key markets, anti-aging and sexual dysfunction, today announced that a study conducted in Europe shows its erectile dysfunction product, Invicorp(TM), is well-tolerated in patients suffering from hypertension, commonly known as high blood pressure. Dr. Wallace Dinsmore, Belfast, North Ireland, studied 21 patients with erectile dysfunction and a history of hypertension, which is common in men with ED. The double blind, placebo controlled study, designed to evaluate Invicorp's tolerance in ED patients with hypertension, included comprehensive measurement of significant variables including systolic blood pressure, diastolic blood pressure, mean arterial pressure, and pulse rates. Study results demonstrated Invicorp was well-tolerated by these patients and is well-suited for use in this population. Dr. Dinsmore said this analysis is consistent with previously observed results. More than one in four adults are believed to have high blood pressure. ``Invicorp is a therapy of great promise compared to existing oral, intracavernous and other therapies from the standpoint of both safety and efficacy,'' Dr. Dinsmore said. He also stated that his research with Invicorp shows it is particularly useful for patients with hypertension. Dr. Dinsmore was involved in the early European studies of Viagra, an oral treatment for ED, and is the Secretary of the British Society for Sexual and Impotence Research. Decision Resources, Inc., in a major report of the potential treatments for ED, said ED in men with hypertension is frequently related to the drugs they take for treatment, although it said withdrawal of the drug does not necessarily restore erectile function. It praised Senetek's product for its rapid onset of action, within two to five minutes, and its safety profile. ``Physicians are enthusiastic about Senetek's new combination injection therapy, which uses vasoactive intestinal polypeptide and phentolamine mesylate,'' the report said. ``We believe it could become the injection therapy of choice.'' Decision Resources has been a world leader in research in pharmaceuticals and the health care industry worldwide for more than 30 years. ``The work by Dr. Dinsmore further reaffirms the advantages that Invicorp possesses as a highly effective treatment for patients with moderate to severe erectile dysfunction, including populations of ED patients who have failed other therapies or who cannot tolerate currently available therapies because of their underlying medical conditions. Millions of men worldwide suffer from ED and we are confident that Invicorp will play an important role in treating a portion of this population,'' said Frank J. Massino, Chairman and CEO. Senetek PLC, headquartered in Napa, Ca., senetekplc.com , is a science-driven biopharmaceutical company engaged in the development of products for anti-aging and sexual dysfunction.<< snipped the boilerplate about forward - looking . . . Cheers, Tuck